Dr. Jason Mellad (CEO) is the Chief Executive Officer at Cambridge Epigenetix. Before joining the company, he served as Business Development Manager at Horizon Discovery and also has extensive experience in the fields of technology transfer, IP management and product innovation consultancy. Jason has a BSc in Molecular Biology and Chemistry from Tulane University and was a Marshall Scholar at the University of Cambridge where he completed a PhD in Medicine.
Deborah Tonge, ACMA (Director of Finance & Operations) spent her early career in the City, training initially with the International Stock Exchange then moving to Lloyds Bank. Following a move to Salomon Smith Barney investment bank she became Management Accountant for the Business Technology Division and then headed a department responsible for Financial Management for Europe and the Financial Division in London. Before joining CEGX Deborah worked for Cambridge Cognition for 5 years while also maintaining a small private practice for small start-up companies in Cambridge and London.
Dr. Vitali Proutski (VP Informatics) is medically qualified and dedicated his career to developing and applying novel informatics and genomics approaches to the discovery and development of medicines and diagnostics. Having worked in both biopharma and CROs, Vitali established teams and facilities serving both internal and external customers, as well as led cross-functional projects applying genomics and informatics methods in early assessment of compound toxicity, safety and efficacy. One of the main focusses of Vitali's career has been the advancement of personalised medicine by means of discovering and developing reliable, clinically-relevant biomarkers and establishing robust biomarker discovery methodologies. In addition to his career in the UK, Netherlands and the US, Vitali spent 3 years with AstraZeneca in Russia, establishing and managing research collaborations and alliances to support global R&D projects and business development activities, as well as leading the Informatics function within the global R&D Information organisation. Most recently, Vitali co-founded National Bioservice LLC, the first fully compliant human biospecimen CRO in Russia with clinical centre parnerships across the country and serving biopharmaceutical customers worldwide. Vitali also co-founded Genext LLC, a clinical testing company that offers patients complex genomic tests from its laboratories in Russia and Estonia.
Dr. Michael Steward (Director of Research & Development) has held numerous scientific leadership roles within the biotech and pharmaceutical sectors with a focus on biopharmaceutical R&D, most recently as head of Antibody Technologies at GSK. During his career, Michael has developed therapeutic and diagnostic antibodies and other molecular tests for a range of diseases and created novel workflows and processes to expedite discovery processes. He is a named author on >30 scientific publications and many patents. Michael’s role at CEGX is to bring forward novel products for detection of epigenetic marks and to make these as accessible as possible to the research and drug discovery community.
Dr. Olga Gandelman MBA, (Director of Assay Development & Services) leads assay development activities at CEGX. Her experience in MDx assay and technology development was gained in successful start-ups and SMEs over 15 years. Prior to CEGX Olga was a Senior Assay Development Manager at Epistem heading a team of world-class scientists working on point-of-care medical, environmental and industrial applications. As a leading scientist at Lumora Ltd, spun-out from Cambridge University that she joined from start-up, Olga was the inventor of Lumora’s proprietary BART technology and several core patents that later led to the acquisition by Roche and ERBA Mannheim. Olga has a first degree and PhD from MSU, Russia, and held postdoctoral research positions with MSU, University of Liverpool, UK (Wellcome Trust Fellowship) and Cambridge University, UK (Daphne Jackson Trust Fellowship).
Dr. Hugh Spotswood (Director of Business Development) leads business development activities at CEGX. He has worked for more than ten years in the research tool industry and joins CEGX from Cancer Research Technology where he headed up the business development team of the organisation’s research tool business - Ximbio. Hugh has also worked in business development at Merck Millipore, Abcam and Orchid Biosciences.